BioSpace News Archive

While MBAs can reflect positively on job applicants, work experience can often be more valuable, depending on the area.

Longitudinal studies that track patients’ experiences can inform and accelerate the drug approval process for rare diseases.

For people with, or at risk for, SOD1-ALS, the FDA’s approval of Qalsody is an important step toward advancing gene-specific research for this uniformly fatal disease.

To be self-employed in the life sciences, you must have a strong network and background and experience in a relevant area.

The French pharma drops another BTK inhibitor program from Principia and an anti-TNFa from Ablynx.

The joint venture between Walgreens and Prothena to accelerate the approval of an Alzheimer’s treatment is the latest in biotech and retail chain alliances.

Vowst, the first-ever oral fecal microbiome-based therapeutic, is indicated for preventing C. diff recurrence in adults following antibacterial treatment.

Merck and AstraZeneca are seeking broad approval for Lynparza in mCRPC regardless of BRCA status.

The leadership shuffle comes as BMS is facing one of the steepest patent cliffs in biopharma, with exclusivity of three of its top drugs lapsing this decade.

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20® (20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcal) serotypes contained in the vaccine in infants and children six weeks through 17 years of age.